痛风治疗市场－2026-2031年预测

预计痛风治疗市场将从 2025 年的 29.26 亿美元成长到 2031 年的 45.13 亿美元，复合年增长率为 7.49%。

预计到2031年，痛风治疗市场将以7.49%的复合年增长率稳定成长，主要驱动因素包括疾病盛行率上升、生活方式改变以及公众意识增强。痛风是由尿酸晶体在关节中积聚引起的关节炎，随着全球患者数量的增加，专门用于控制和缓解痛风症状的治疗方法日益受到重视。痛风盛行率上升、生活方式改变、肥胖率上升、持续的研究、新产品上市、政府支持以及公众意识增强等因素都在推动市场扩张。

主要市场驱动因素

痛风发病率上升

全球痛风盛行率显着上升，对有效治疗方法的需求持续成长。一项基于临床实务研究资料库（CPRD）资料的全国性队列研究（发表于2021年6月的《风湿病年鑑》）显示，1997年至2021年间（包括新冠疫情期间），痛风盛行率从0.98​​%上升至2.33%。过去二十年间盛行率翻番，凸显了需要治疗性介入的患者人数不断增加，也成为推动市场成长的根本动力，因为医疗保健系统正在积极应对日益增长的治疗需求。

与肥胖有关

肥胖和痛风是相互关联的疾病，肥胖被认为是痛风发生的重要危险因子。超重者，尤其是腹型肥胖者，尿酸合成增加，尿酸排泄减少，导致尿酸水平升高，诱发痛风。全球肥胖盛行率的不断上升预计将显着推动痛风治疗市场的发展。肥胖已达到流行病的程度，每年造成约280万人死亡。根据《2022年世界肥胖地图集》，预计到2031年，五分之一的女性和七分之一的男性将患有肥胖症。这意味着，与肥胖相关的痛风病例数量的不断增加将持续对痛风治疗的需求构成压力。

生活方式因素

生活方式的选择在痛风的发生、控制和预防中起着关键作用。某些行为，例如饮食选择、饮酒、吸烟和压力，都可能导致痛风发作或加重症状。酒精，尤其是啤酒和烈酒，与痛风风险增加密切相关。 2020年，美国21岁以上成年人平均每人每年消费26加仑啤酒和苹果酒。这种高酒精消费量，加上久坐等生活方式的改变，都是现代社会普遍存在的可改变的风险因素，也是痛风药物市场成长要素。

提高认识和诊断水平

医疗专业人员和民众对痛风的认识不断提高，诊断率也随之提升。早期准确诊断有助于儘早开始治疗，从而推动了痛风药物的需求。美国疾病管制与预防中心（CDC）关节炎计画建议了五种有效的自我管理策略，用于治疗关节炎及相关症状，这些策略对痛风患者同样有益。 5月22日被定为美国的“痛风宣传日”，旨在提高公众对痛风不良反应和治疗方案的认识。美国国家痛风教育协会、痛风宣传联盟和美国肾臟病患者协会等组织正积极进行痛风宣传活动。这些有组织的宣传活动和不断提高的社会意识鼓励患者寻求适当的医疗干预，从而促进了市场成长。

研究与开发活动

针对痛风治疗的研究和临床试验的增加，以及随后产品的上市，预计将推动市场成长。由InventisBio公司开发的D-0120目前正处于治疗痛风性关节炎的II期临床开发阶段。由Selecta Biosciences公司开发的用于治疗慢性难治性痛风的SEL-212的III期Dissolve计画已于2023年3月完成，其中Dissolve I和Dissolve II计画显示，在50岁及以上患者中，较高剂量组的缓解率具有统计学意义上的显着提高。这些正在进行的临床开发表明，业界致力于拓展治疗选择，并满足痛风治疗领域尚未满足的需求。

市场限制

儘管痛风治疗市场呈现成长趋势，但仍面临诸多挑战。痛风需要长期照护和生活方式调整，然而有些患者难以坚持治疗方案，尤其是在药物依从性、饮食调整和健康生活习惯方面。依从性差会增加疾病进展的风险，并因症状控制不佳而降低治疗效果。此外，痛风治疗的副作用，从轻微到严重不等，也可能限制市场成长。长期使用皮质类固醇可能引起全身性副作用，这可能导致部分患者无法坚持治疗。

区域和近期趋势

由于痛风发病率上升、医疗基础设施完善以及医疗费用支出不断增长，预计北美在预测期内将占据显着的市场份额。美国医疗支出占GDP的比例从2019年的16.68%成长到2020年的18.82%。默克和梅奥诊所等主要市场参与者预计将透过产品改进推动区域市场成长。

近期发展凸显了持续创新的重要性。 2022年8月，ThinkLogic宣布推出SYNB2081，这是一种与Ginkgo Bioworks合作，利用合成生物技术开发的候选药物。该药物旨在降低尿酸水平。在流行病学趋势、研究进展以及人们对痛风临床和经济负担日益增长的认识的推动下，痛风治疗市场持续发展。

本报告的主要优势：

• 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
• 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
• 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
• 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
• 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

• 历史资料（2021-2025 年）和预测资料（2026-2031 年）
• 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
• 竞争对手定位、策略和市场占有率分析
• 按业务板块和地区（国家）分類的收入成长和预测分析
• 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策和法规
• 策略建议

第四章 技术展望

5. 痛风治疗药物市场

• 介绍
• 非类固醇消炎剂（NSAIDs）
• 皮质类固醇
• 秋水仙碱
• 降低尿酸的药物
• 其他的

第六章 依症状分類的痛风治疗市场

• 介绍
• 急性痛风
• 慢性痛风

7. 痛风治疗市场依通路划分

• 介绍
• 医院药房
• 零售药房
• 网路药房

8. 各地区痛风治疗市场

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 企业合併、协议、商业合作
• 竞争对手仪錶板

第十章：公司简介

• Takeda Pharmaceutical Company Ltd.
• Novartis AG
• AstraZeneca plc
• Horizon Therapeutics plc
• Merck & Co. Inc.
• Teijin Pharma Ltd.
• GlaxoSmithKline, Plc.
• Arthrosi
• Mayo Clinic
• Johns Hopkins Arthritis Center

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 分析方法
• 简称

The gout therapeutics market, with a 7.49% CAGR, is forecasted to rise from USD 2.926 billion in 2025 to USD 4.513 billion in 2031.

The gout therapeutics market is experiencing steady growth at a 7.49% CAGR through 2031, driven by increasing disease prevalence, lifestyle changes, and enhanced awareness. Gout therapeutics-treatments specifically designed to manage and alleviate symptoms of this arthritis form caused by uric acid crystal buildup in joints-are becoming increasingly critical as patient populations expand globally. Rising gout prevalence, changing lifestyles, higher obesity rates, ongoing research, product launches, government support, and growing public awareness are propelling market expansion.

Primary Market Drivers

Rising Gout Prevalence

Gout prevalence has increased substantially worldwide, creating sustained demand for effective therapeutics. A nationwide cohort study using Clinical Practice Research Datalink data published in the Annals of Rheumatic Diseases in June 2021 demonstrated that gout prevalence climbed from 0.98% in 1997 to 2.33% in 2021, spanning the COVID-19 pandemic. This more than doubling of prevalence over two decades underscores the growing patient population requiring therapeutic intervention and represents a fundamental driver of market growth as healthcare systems address expanding treatment needs.

Obesity Connection

Obesity and gout are interconnected conditions, with obesity recognized as a significant risk factor for gout development. Overweight individuals, particularly those with abdominal obesity, experience increased uric acid synthesis and decreased uric acid excretion, elevating uric acid levels that precipitate gout. The rising global obesity prevalence is contemplated to substantially aid the gout therapeutics market. Obesity has reached epidemic proportions, causing approximately 2.8 million deaths annually. The World Obesity Atlas 2022 estimates that 1 in 5 women and 1 in 7 men will live with obesity by 2031, indicating sustained pressure on gout therapeutics demand as obesity-related gout cases accumulate.

Lifestyle Factors

Lifestyle choices play crucial roles in gout development, management, and prevention. Certain behaviors-including dietary choices, alcohol consumption, smoking, and stress-can contribute to gout onset or exacerbate symptoms. Alcohol, particularly beer and spirits, has been associated with increased gout risk. Individuals aged 21 and above in the United States consumed an average of 26 gallons of beer and hard cider per person in 2020. This substantial alcohol consumption, combined with changing lifestyle patterns such as sedentary behavior adoption, represents a major growth driver for the gout therapeutics market as these modifiable risk factors remain prevalent in modern societies.

Awareness and Diagnosis Improvements

Increased awareness about gout among healthcare professionals and the general population has led to improved diagnosis rates. Early and accurate diagnosis enables timely treatment initiation, promoting gout therapeutics demand. The CDC's Arthritis Program advises five self-management techniques for treating arthritis and related symptoms that may benefit gout patients. May 22 is celebrated as Gout Awareness Day in America to raise public awareness about adverse effects and treatment options. Organizations including the National Gout Education Society, Alliance for Gout Awareness, and American Association of Kidney Patients actively promote gout awareness. These institutional efforts and rising public consciousness are propelling market growth by ensuring patients seek appropriate medical intervention.

Research and Development Activity

Increasing studies and clinical trials for gout treatment, followed by product launches, are anticipated to boost market growth. D-0120 is under phase II clinical development for gouty arthritis, developed by InventisBio. The phase 3 Dissolve program of SEL-212 developed by Selecta Biosciences to treat chronic refractory gout concluded in March 2023, showing statistically significant higher response rates in patients 50 years and above at high doses in Dissolve I and Dissolve II. These ongoing clinical developments demonstrate industry commitment to advancing therapeutic options and addressing unmet medical needs in gout management.

Market Constraints

Despite positive growth trajectories, the gout therapeutics market faces challenges. Gout demands long-term care and lifestyle modifications, yet some patients struggle with treatment plan adherence, including medication compliance, dietary changes, and healthy lifestyle adoption. Non-compliance may compromise therapeutic effectiveness by raising disease progression risk and resulting in insufficient symptom management. Additionally, adverse effects of gout therapeutics-ranging from minor to serious-may limit market growth. Corticosteroids may produce systemic adverse effects when used over extended periods, potentially deterring some patients from sustained treatment.

Regional Dynamics and Recent Developments

North America is expected to hold significant market share during the forecast period, supported by rising gout incidence, strong healthcare infrastructure, and increasing healthcare expenditure. Health expenditure as a U.S. GDP percentage increased from 16.68% in 2019 to 18.82% in 2020. Major market players including Merck & Co. and Mayo Clinic are expected to bolster regional market growth through enhanced products.

Recent developments underscore ongoing innovation. In August 2022, Synglogic Inc. launched SYNB2081, a new drug candidate for gout treatment developed through synthetic biology in collaboration with Ginkgo Bioworks, designed to lower uric acid levels. The gout therapeutics market continues evolving, propelled by epidemiological trends, research advancement, and growing recognition of gout's clinical and economic burden.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Gout Therapeutics Market Segmentation

• By Drug Class
• NSAIDs
• Corticosteroids
• Colchicine
• Urate-Lowering Agents
• Others
• By Disease Condition
• Acute Gout
• Chronic Gout
• By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GOUT THERAPEUTICS MARKET BY DRUG CLASS

• 5.1. Introduction
• 5.2. NSAIDs
• 5.3. Corticosteroids
• 5.4. Colchicine
• 5.5. Urate-Lowering Agents
• 5.6. Others

6. GOUT THERAPEUTICS MARKET BY DISEASE CONDITION

• 6.1. Introduction
• 6.2. Acute Gout
• 6.3. Chronic Gout

7. GOUT THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Retail Pharmacy
• 7.4. Online Pharmacy

8. GOUT THERAPEUTICS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Takeda Pharmaceutical Company Ltd.
• 10.2. Novartis AG
• 10.3. AstraZeneca plc
• 10.4. Horizon Therapeutics plc
• 10.5. Merck & Co. Inc.
• 10.6. Teijin Pharma Ltd.
• 10.7. GlaxoSmithKline, Plc.
• 10.8. Arthrosi
• 10.9. Mayo Clinic
• 10.10. Johns Hopkins Arthritis Center

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations